Table 2. Evaluation of human STAT3/p-STAT3 by IHC in the selected studies.
| References | Type of cancer | Marker | Cutoff | Antibody (Clone) |
|---|---|---|---|---|
| Abou-Ghazal, M., et al. (2008) | Gliomas | p-STAT3 | NR | anti-p-STAT3 (Tyr705), Cell Signaling Technology |
| Ai, T., et al. (2012) | NSCLC | STAT3 | IHC > 51% | anti-STAT3, Cell Signaling Technology |
| Birner, P., etal. (2010) | Gliomas | p-STAT3 | IHC ≥ 5% | anti-p-STAT3 (Tyr705), clone D3A7, Cell Signaling |
| Chang, K. C., et al. (2006) | TET | STAT3 | IHC ≥ 10% | anti-Stat3 F-2: sc-8019, Santa Cruz Biotechnology, Inc. |
| Chatterjee, Devasis., et al. (2008) | GC | STAT3-nuclear | IHC scores ≥ 4 | anti-STAT3, Santa Cruz Biotechnology, Inc. |
| Chen, H. H., et al. (2012) | CC | STAT3 | IHC ≥ 20% | anti-STAT3, Santa Cruz Biotechnology, Inc. |
| Chen, C. C., et al. (2010) | NC | p-STAT3 | IHC > 10% | NR |
| Choi, Chel Hun., et al. (2010) | CC | p-STAT3 | IHC > 51% | anti-p-STAT3 (ser727), Santa Cruz Biotechnology |
| Cortas, T., et al. (2007) | NSCLC | p-STAT3 | IHC ≥ 5% | anti-p-STAT3 (sc-8059), Santa Cruz Biotechnology |
| Deng, J. Y., et al. (2010) | GC | p-STAT3 | ≥ 10% | anti-p-STAT3 (sc-483) |
| Deng, J., et al. (2013) | GC | p-STAT3 | IHC > 25% | anti-p-STAT3, Santa, sc-8001-R |
| Denley, S. M., et al. (2013) | PDA | p-STAT3 | IHC ≥ 2% | anti-pStat3 Tyr 705, 9131, Cell Signaling Technology |
| anti-pStat3 (Ser 727), 9134, Cell Signaling Technology | ||||
| Dobi, E., et al. (2013) | CRC | p-STAT3 | IHC > 15% | anti-p-STAT3, sc-7993, Santa Cruz Biotechnology |
| Dolled-Filhart, M., et al. (2003) | BC | STAT3-cytoplasmic | IHC score ≥ 1 | anti-STAT3, Cell Signaling Technology |
| STAT3-nuclear | anti-STAT3, Cell Signaling Technology | |||
| p-STAT3-cytoplasmic | anti-p-STAT3 (Tyr 705), Cell Signaling Technology | |||
| p-STAT3-nuclear | anti-p-STAT3 (Tyr 705), Cell Signaling Technology | |||
| Galleges Ruiz, M. I., et al. (2009) | NSCLC | p-STAT3-nuclear | IHC score > 210 | anti–p-STAT3 |
| Gordziel, C., et al. (2013) | CRC | STAT3-cytoplasmic | IHC score ≥ 2 | anti-STAT3: Stat3 (79D7), Cell Signaling Technology |
| STAT3-nuclear | ||||
| Haura, Eric B., et al. (2005) | NSCLC | p-STAT3-nuclear | IHC score ≥ 1 | anti-p-Stat3 (Tyr 705), Cell Signaling Technology |
| Hbibi, A. Tadlaoui., et al. (2008) | CRC | p-STAT3 | IHC score ≥ 6 | anti-P-STAT3 (Tyr 705), Cell Signaling Technology |
| STAT3 | anti-STAT3, Cell Signaling | |||
| Horiguchi, Akio., et al. (2002) | RCC | p-STAT3 | IHC ≥ 10% | anti-p-STAT3, (Tyr 705), Cell Signaling Technology |
| Huang, C., et al. (2012) | PDA | p-STAT3 | IHC ≥ 25% | anti-p-STAT3, Cell Signaling Technology |
| Jia, Yanfei., et al. (2013) | GC | STAT3 | NR | anti-STAT3, Santa Cruz Biotechnology |
| Kim, D. Y., et al. (2009) | GC | STAT3 | NR | anti-STAT3, Chemicon International |
| Kim, Yeon-Joo., et al. (2011) | NC | STAT3 | IHC ≥ 10% | anti-STAT3, Epitomics |
| Kusaba, T., et al. (2006) | CRC | p-STAT3 | IHC > 15% | anti-p-STAT3 (Tyr705), Santa Cruz Biotechnology |
| Lee, I., et al. (2012) | Melanoma | p-STAT3 | IHC ≥ 1% | anti-p-STAT3 (Tyr705), Santa Cruz Biotechnology |
| Lee, J., et al. (2009) | GC | p-STAT3 | IHC ≥ 1% | anti-p-STAT3 (Tyr705), Cell Signaling Technology |
| Li, Chao., et al. (2013) | TET | STAT3 | IHC > 10% | anti-STAT3, Santa Cruz Biotechnology |
| Li, X., et al. (2015) | NSCLC | STAT3 | IHC score ≥ 4 | anti-STAT3, Santa Cruz Biotechnology |
| Lin, G. S., et al. (2014) | Gliomas | p-STAT3 | IHC > 5% | anti-p-STAT3 (Tyr705), D3A7, Cell Signaling |
| Macha, Muzafar A., et al. (2011) | Oral cancer | p-STAT3 | NR | anti-p-STAT3 (Tyr 705), Cell Signaling |
| Mano, Y., et al. (2013) | HC | p-STAT3 | NR | anti-p-STAT3 (Tyr 705), D3A7, Cell Signaling |
| Min, Hao., et al. (2009) | OC | STAT3 | IHC ≥ 10% | anti-Stat3, (SC-8019), Santa Cruz Biotechnology |
| p-STAT3 | IHC ≥ 10% | anti-p-Stat3 (Tyr 705), ZP-0647, Abzoom Biotechnology | ||
| Monnien, F., et al. (2010) | CRC | p-STAT3 | IHC > 15% | anti-p-Stat3 (Tyr 705), sc-7993, Santa Cruz |
| Pectasides, Eirini., et al. (2010) | HNSCC | STAT3-nuclear | NR | anti-Stat3, clone 124H6; Cell Signaling Technology |
| Piperi, Christina., et al. (2011) | Gliomas | p-STAT3 | IHC ≥ 6% | anti-p-STAT3 (Tyr 705), D3A7 XP, Cell Signaling |
| Rosen, D. G., et al. (2006) | OC | p-STAT3 | IHC > 10% | anti-p-Stat3, (SC-7993-R), Santa Cruz Biotechnology |
| Ryu, Keinosuke., et al. (2010) | Osteosarcoma | p-STAT3 | IHC > 51% | anti-p-STAT, Cell Signaling Technology |
| Schoppmann, Sebastian F., et al. (2012) | EC | p-STAT3 | IHC > 10% | anti-p-STAT3 (Tyr 705), D3A7, Cell Signaling |
| Shah, N. G., et al. (2006) | OSCC | STAT3-nuclear | IHC > 10% | anti-STAT3, Santa Cruz Biotechnology |
| Slinger, E., et al. (2010) | Gliomas | p-STAT3 | IHC > 30% | anti-p-STAT3, (Tyr 705), Cell Signaling |
| Sheen-Chen, Shyr-Ming., et al. (2008) | BC | STAT3 | IHC score ≥ 3 | anti-STAT3 (RB-9237), NeoMarkers |
| Sonnenblick, A., et al. (2012) | BC | p-STAT3 | IHC ≥ 25% | anti-p-STAT3, (Tyr 705), Cell Signaling |
| Sonnenblick, A., et al. (2013) | BC | p-STAT3 | IHC ≥ 10% | anti-p-STAT3, (Tyr 705), Cell Signaling |
| Takemoto, S., et al. (2009) | CC | p-STAT3 | IHC ≥ 5% | anti-p-Stat3 (Tyr 705), sc-7993, Santa Cruz Biotechnology |
| Tam, L., et al. (2007) | PC | p-STAT3-cytoplasmic | ICCC > 0.7 | anti-p-STAT3 (Tyr 705), 9131, Cell Signaling |
| p-STAT3-nuclear | ||||
| van Cruijsen, H., et al. (2009) | NSCLC | p-STAT3 | NR | anti-p-STAT3 (Tyr 705), clone D3A7, Cell Signaling |
| Wang, M., et al. (2011) | NSCLC | p-STAT3 | IHC > 25% | anti-p-STAT3, Cell Signaling Technology |
| Wang, Y., et al. (2011) | Gliomas | p-STAT3 | IHC score > 4 | anti-p-STAT3 (Tyr 705), clone D3A7, Cell Signaling |
| Wang, Y. C., et al. (2011) | Osteosarcoma | STAT3 | IHC > 5% | anti-STAT3, Santa Cruz Biotechnology |
| Wu, Zheng-Sheng., et al. (2011) | Melanoma | p-STAT3 | NR | anti-p-STAT3, Santa Cruz Biotechnology |
| Woo, S., et al. (2011) | GC | p-STAT3 | IHC ≥ 1% | anti-p-STAT3, (Tyr 705), Cell Signaling |
| Xiong, Hua., et al. (2012) | GC | STAT3 | IHC > 15% | anti-STAT3 |
| p-STAT3 | anti-p-STAT3 (Tyr 705) | |||
| Yakata, Yuichi., et al. (2007) | GC | p-STAT3 | IHC > 10% | anti-p-STAT3, Santa Cruz Biotechnology |
| Yamashita, H., et al. (2006) | BC | STAT3 | IHC score ≥ 2 | anti-STAT3, (F-2), Santa Cruz Biotechnology |
| Yang, C., et al. (2013) | OC | p-STAT3 | IHC > 50% | anti-p-STAT3, (Tyr 705), Cell Signaling Technology |
| Yang, Cao., et al. (2009) | Chordoma | p-STAT3 | IHC score ≥ 4 | anti-p-STAT3, Cell Signaling Technology |
| Yin, Z., et al. (2012) | NSCLC | STAT3 | IHC ≥ 50% | anti-STAT3, (sc-8019); Santa Cruz |
| You, Z., et al. (2012) | EC | p-STAT3 | IHC score ≥ 2 | anti-p-STAT3, (Tyr 705), Cell Signaling Technology |
| Yu, Y., et al. (2015) | NSCLC | pSTAT3 | IHC score ≥ 3 | NR |
| Zhang, C. H., et al. (2012) | HC | STAT3 | IHC > 10% | anti-STAT3, Santa Cruz Biotechnology |
| p-STAT3 | anti-p-STAT3, (Tyr 705), Cell Signaling Technology | |||
| Zhang, L. J., et al. (2013) | Wilms' tumor | STAT3 | IHC > 51% | anti-STAT3, (sc-7179), Santa Cruz Biotechnology |
| Zhao, X., et al. (2012) | SCLC | STAT3 | IHC ≥ 25% | anti-STAT3, Wuhan Boster Company |
| p-STAT3 | anti-p-STAT3, clone B-7, Wuhan Boster Company | |||
| Zhao, Yan., et al. (2012) | LSCC | STAT3 | IHC ≥ 10% | anti-STAT3, Santa Cruz Biotechnology |
NSCLC: Non-Small Cell Lung Cancer; GC: Gastric cancer; CRC: Colorectal Cancer; BC: Breast cancer; CC: Cervical Carcinoma; OC: Ovarian Carcinoma; PDA: Pancreatic Ductal Adenocarcinoma; TET: Thymic Epithelial Tumours; RCC: Renal Cell Carcinoma; HC: Hepatocellular Carcinoma; HNSCC: Head and Neck Squamous Cell Carcinoma; EC: Esophageal Cancer; OSCC: Oral Squamous Cell Carcinoma; SCLC: Small Cell Lung Cancer; NC: Nasopharyngeal carcinoma; LSCC: Lingual Squamous Cell Carcinoma; PC: Prostate Cancer; ICCH: Interclass Correlation Coefficient; NR: Not Reported.